Efficacy and Safety of PF ‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

ConclusionTreatment with the oral JAK3/TEC inhibitor PF ‐06651600 (200 mg once daily) was associated with significant improvements in RA disease activity and was generally well‐tolerated in this small 8‐week study.

Source: Arthritis and Rheumatology - September 6, 2020 Category: Rheumatology Authors: Michael F. Robinson, Nemanja Damjanov, Bojana Stamenkovic, Goran Radunovic, Alan Kivitz, Lori Cox, Zorayr Manukyan, Christopher Banfield, Michael Saunders, Deepa Chandra, Michael S. Vincent, Jessica Mancuso, Elena Peeva, Jean S. Beebe Tags: Full Length Source Type: research